Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

19.3K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.3K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

493
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
493
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

453
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
453
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.7K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.2K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

566
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
566

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differences in biomarkers and molecular pathways according to age for patients with HFrEF.

Cardiovascular research·2020
Same author

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials.

European journal of heart failure·2020
Same author

Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: insights from the RELAX-AHF-2 study.

European journal of heart failure·2020
Same author

Drug development in oncology and devices-lessons for heart failure drug development and approval? a review.

Heart failure reviews·2020
Same author

The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction.

Cardiovascular research·2020
Same author

A Clinical Tool to Predict Low Serum Selenium in Patients with Worsening Heart Failure.

Nutrients·2020

Related Experiment Video

Updated: Mar 9, 2026

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
09:40

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle

Published on: January 19, 2017

12.3K

Expert consensus document: Mitochondrial function as a therapeutic target in heart failure.

David A Brown1, Justin B Perry1, Mitchell E Allen1

  • 1Department of Human Nutrition, Foods, and Exercise, Virginia Tech, 1035 Integrated Life Sciences Building, 1981 Kraft Drive, Blacksburg, Virginia 24060, USA.

Nature Reviews. Cardiology
|December 23, 2016
PubMed
Summary
This summary is machine-generated.

Heart failure therapies improve symptoms but not cardiomyocyte molecular issues. Targeting mitochondrial dysfunction offers a promising therapeutic strategy to enhance cardiac function in heart failure patients.

More Related Videos

Author Spotlight: Uncovering the Role of Mitochondrial Calcium Phosphate in Heart Failure and Bioenergetics
07:03

Author Spotlight: Uncovering the Role of Mitochondrial Calcium Phosphate in Heart Failure and Bioenergetics

Published on: August 23, 2024

1.6K
Author Spotlight: Exploring Mitochondrial Function and Chemical Toxicity Using Drosophila melanogaster
09:20

Author Spotlight: Exploring Mitochondrial Function and Chemical Toxicity Using Drosophila melanogaster

Published on: November 10, 2023

1.5K

Related Experiment Videos

Last Updated: Mar 9, 2026

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
09:40

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle

Published on: January 19, 2017

12.3K
Author Spotlight: Uncovering the Role of Mitochondrial Calcium Phosphate in Heart Failure and Bioenergetics
07:03

Author Spotlight: Uncovering the Role of Mitochondrial Calcium Phosphate in Heart Failure and Bioenergetics

Published on: August 23, 2024

1.6K
Author Spotlight: Exploring Mitochondrial Function and Chemical Toxicity Using Drosophila melanogaster
09:20

Author Spotlight: Exploring Mitochondrial Function and Chemical Toxicity Using Drosophila melanogaster

Published on: November 10, 2023

1.5K

Area of Science:

  • Cardiology
  • Molecular Biology
  • Biochemistry

Background:

  • Heart failure is a global health crisis with millions affected and a poor prognosis despite current treatments.
  • Existing therapies offer symptomatic relief but fail to address underlying molecular abnormalities in cardiomyocytes.
  • Viable but dysfunctional myocardium in heart failure patients presents an opportunity for functional improvement.

Purpose of the Study:

  • To elucidate the mechanisms of mitochondrial dysfunction in heart failure.
  • To review emerging therapeutic strategies targeting mitochondria for heart failure treatment.

Main Methods:

  • This consensus statement synthesizes current research on mitochondrial dysfunction in heart failure.
  • It reviews emerging therapeutic approaches focused on mitochondrial targets.

Main Results:

  • Mitochondrial dysfunction is a key factor in heart failure pathophysiology.
  • Abnormalities include impaired electron transport chain, increased reactive oxygen species, altered metabolism, dynamics, and ion homeostasis.
  • Emerging treatments aim to directly improve mitochondrial function.

Conclusions:

  • Mitochondrial dysfunction is a critical therapeutic target for improving cardiac function in heart failure.
  • Targeting mitochondria holds potential for novel treatments to address molecular deficits in heart failure.
  • Further research into mitochondrial-based therapies is warranted for heart failure management.